the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More

NCT06622603 · clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
59
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Seoul National University Hospital

Collaborators